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Abstract

Key Points

IMPORTANCE Although prescribers face numerous patient-centered challenges during transitions
of care (TOC) at hospital discharge, prolonged duration of antimicrobial therapy for common
infections remains problematic, and resources are needed for antimicrobial stewardship throughout
this period.

Question Are antimicrobial
stewardship interventions during
transitions of care associated with
improved prescribing of antimicrobials
at hospital discharge?

OBJECTIVE To evaluate a pharmacist-driven intervention designed to improve selection and

Findings In this quality improvement

duration of oral antimicrobial therapy prescribed at hospital discharge for common infections.

study of 800 patients, a pharmacistdriven intervention targeting

DESIGN, SETTING, AND PARTICIPANTS This quality improvement study used a nonrandomized

antimicrobial prescribing at discharge

stepped-wedge design with 3 study phases from September 1, 2018, to August 31, 2019. Seventeen

was associated with higher frequency of

distinct medicine, surgery, and specialty units from a health system in Southeast Michigan

optimal antimicrobial regimens

participated, including 1 academic tertiary hospital and 4 community hospitals. Hospitalized adults

compared with before the intervention.

who had urinary, respiratory, skin and/or soft tissue, and intra-abdominal infections and were

Patients in the postintervention group

prescribed antimicrobials at discharge were included in the analysis. Data were analyzed from

had similar rates of mortality,

February 18, 2020, to February 28, 2022.

readmission, and clinical resolution and
fewer severe antimicrobial-related

INTERVENTIONS Clinical pharmacists engaged in a new standard of care for antimicrobial

adverse effects compared with the

stewardship practices during TOC by identifying patients to be discharged with a prescription for oral

preintervention group.

antimicrobials and collaborating with primary teams to prescribe optimal therapy. Academic and
community hospitals used both antimicrobial stewardship and clinical pharmacists in a

Meaning These findings suggest that
hospitals can leverage resources toward

multidisciplinary rounding model to discuss, document, and facilitate order entry of the antimicrobial
prescription at discharge.

antimicrobial stewardship during
transitions of care to optimize
antimicrobial therapy.

MAIN OUTCOMES AND MEASURES The primary end point was frequency of optimized
antimicrobial prescription at discharge. Health system guidelines developed from national guidelines
and best practices for short-course therapies were used to evaluate optimal therapy.

+ Supplemental content

RESULTS A total of 800 patients prescribed oral antimicrobials at hospital discharge were included

Author affiliations and article information are
listed at the end of this article.

in the analysis (441 women [55.1%]; mean [SD] age, 66.8 [17.3] years): 400 in the preintervention
period and 400 in the postintervention period. The most common diagnoses were pneumonia (264
[33.0%]), upper respiratory tract infection and/or acute exacerbation of chronic obstructive
pulmonary disease (214 [26.8%]), and urinary tract infection (203 [25.4%]). Patients in the
postintervention group were more likely to have an optimal antimicrobial prescription (time-adjusted
generalized estimating equation odds ratio, 5.63 [95% CI, 3.69-8.60]). The absolute increase in
optimal prescribing in the postintervention group was consistent in both academic (37.4% [95% CI,
27.5%-46.7%]) and community (43.2% [95% CI, 32.4%-52.8%]) TOC models. There were no
differences in clinical resolution or mortality. Fewer severe antimicrobial-related adverse effects
(continued)
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Abstract (continued)

(time-adjusted generalized estimating equation odds ratio, 0.40 [95% CI, 0.18-0.88]) were
identified in the postintervention (13 [3.2%]) compared with the preintervention (36 [9.0%]) groups.
CONCLUSIONS AND RELEVANCE The findings of this quality improvement study suggest that
targeted antimicrobial stewardship interventions during TOC were associated with increased
optimal, guideline-concordant antimicrobial prescriptions at discharge.
JAMA Network Open. 2022;5(5):e2211331. doi:10.1001/jamanetworkopen.2022.11331

Introduction
In the US, 1 in 5 hospitalized adults is prescribed an antimicrobial at the time of discharge, accounting
for millions of antimicrobial-days each year.1 Although prescribers face numerous patient-centered
challenges during transitions of care (TOC), resources are sorely needed for antimicrobial
stewardship throughout this period.2 In a statewide collaborative effort, the Michigan Hospital
Medicine Safety Consortium classified the appropriateness of more than 20 000 antimicrobials
prescribed at discharge, and nearly half were considered overuse.3 The most common antimicrobial
class prescribed at discharge, the fluoroquinolone, has a number of box warnings and safety
concerns, yet as few as 25% of these orders are considered appropriate.1,4,5 Prolonged duration of
antimicrobial therapy is consistently the major contributor to inappropriate prescribing during TOC,
and a mean of 40% of each patients’ total duration of therapy is administered post discharge.1,3,6 The
review of antimicrobial prescribing during TOC represents a crucial moment in a patient’s clinical
course to ensure safe, effective, and guideline-concordant therapy.
Few antimicrobial stewardship interventions have been targeted in the collaborative discharge
planning process.7-9 Traditional inpatient antimicrobial stewardship initiatives such as audit and
feedback may not impact prescribing practices at discharge.10,11 The Centers for Disease Control and
Prevention core elements of outpatient antibiotic stewardship12 identify transition from acute care
to other health care settings as an opportunity to improve the quality of prescribing. Physicians,
pharmacists, nurses, and case managers at the front lines of patient care have the tools to collaborate
and optimize antimicrobial therapy at discharge.9 The purpose of this study was to (1) implement a
pharmacist-led, multidisciplinary review of discharge planning for oral antimicrobial therapy; (2)
quantify inappropriate antimicrobial prescribing at the time of discharge; and (3) evaluate the
association of the intervention with optimized antimicrobial therapy, infection-related readmissions,
and antimicrobial-associated harms.

Methods
Study Setting and Design
This quality improvement study used a nonrandomized stepped-wedge design to evaluate an
antimicrobial stewardship intervention for adults discharged from the hospital with antimicrobial
prescriptions for select uncomplicated infections. From September 1, 2018, to August 31, 2019, 5
hospitals within the Henry Ford Health System in southeastern Michigan participated in this study,
including Henry Ford Hospital (a 877-bed academic medical center in Detroit), Henry Ford Allegiance
Hospital (a 475-bed community hospital in Jackson), Henry Ford Wyandotte Hospital (a 401-bed
community hospital in Wyandotte), Henry Ford Macomb Hospital (a 361-bed community hospital in
Clinton Township), and Henry Ford West Bloomfield Hospital (a 191-bed community hospital in West
Bloomfield). Each hospital had at least a partial full-time equivalent for an antimicrobial stewardship
pharmacist (0.8-1.0 full-time equivalent) and physician (0.2-0.8 full-time equivalent), and clinical
pharmacists were integrated within medical teams. The intervention was implemented across all
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sites in a nonrandomized order. This intervention was selected for feasibility of implementing a new
standard of care at TOC with the available resources in the health system. The stepped-wedge design
also allowed control for regression to the mean, maturation effects, and confounding due to secular
trends in a health system–wide intervention that implemented the TOC initiative for 3 phases
(Table 1) that were selected in order of institutional readiness.13 The study was approved by the
health system’s ethics committee as a quality improvement initiative, and a waiver of informed
consent was granted by the institutional review board. This study followed the Standards for Quality
Improvement Reporting Excellence (SQUIRE 2.0) reporting guideline.

Intervention
The objective of the intervention was to facilitate optimal antimicrobial discharge prescriptions by
leveraging the existing pharmacy practice model for TOC with local antimicrobial use and duration
guidelines through collaboration with the primary team. The antimicrobial stewardship intervention
at TOC was implemented in 3 phases in 17 distinct units (service teams) across the 5 hospitals. Order
of intervention rollout was prioritized based on patient volume, availability of resources, and
pharmacist training. Group 1 consisted of units at an academic hospital; group 2, both academic and
community hospital units; and group 3, community hospital units (Table 1). The TOC model enabled
clinical and antimicrobial stewardship pharmacists to identify patients approaching discharge with
active antimicrobial orders, to create and communicate collaborative plans related to antimicrobial
selection and duration of therapy, and to enter the antimicrobial prescription with a stop date to be
signed by the primary clinician at discharge. Local physician champions were identified on each
service team to promote intervention uptake.14
Clinical pharmacists involved with the intervention were trained in mandatory competency
sessions to optimally manage workflow and the operational components for antimicrobial order
entry. Before discharge, the pharmacist reviewed an inpatient team census in the electronic health
record that included all active antimicrobials at the start of each shift. Patients were reviewed to
identify those with qualifying diagnoses of infectious diseases who may be eligible to complete the
antimicrobial course with oral therapy after discharge. In the academic center setting, clinical
pharmacists assessed discharge readiness with a notification in the electronic team census in
addition to daily discussions on collaborative rounds with nurses, physicians, nurse practitioners,
physician assistants, and case managers. To identify patients with anticipated discharge in
community hospital settings, antimicrobial stewardship pharmacists were alerted in different ways
depending on reporting structures specific to each institution. These methods included electronic
team census notifications, direct communication from nursing and case management, and/or
discussions during collaborative team rounds. Cost inquiries for oral antimicrobials were requested
on a case-by-case basis via electronic order to the outpatient pharmacist to address financial

Table 1. Description of Service Teams in Study Groups and Timeline of Nonrandomized, Stepped-Wedge Design
and Interventions

Study group

Quarter 1:
August to
October 2018
(n = 125)

Preintervention
Group 1 (n = 250):
academic hospital service teams
including internal medicine,
pulmonology, family medicine,
and infectious diseases

Quarter 2:
November 2018 to
February 2019
(n = 300)

Quarter 3:
March to
May 2019
(n = 225)

Quarter 4:
June to
August 2019
(n = 150)

Intervention in
place

Intervention in
place

Intervention in
place

Group 2 (n = 275):
academic and community
hospital service teams including
nephrology, cardiology, family
medicine, and internal medicine

Preintervention

Preintervention

Intervention in
place

Intervention in
place

Group 3 (n = 275):
community service teams
including hospitalist and
internal medicine

Preintervention

Preintervention

Preintervention

Intervention in
place
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barriers.15 Documentation in the electronic medical record was completed by the clinical pharmacist
to describe the agent, indication, dose, and duration of therapy for patients during the study period.
The discharging prescriber received recommendations for the protocolized antimicrobial regimen
during TOC on collaborative rounds or via telephone. After the antimicrobial plan was discussed, the
orders for discharge were entered or modified (if needed) in the electronic discharge queue by the
pharmacist to be cosigned by the prescriber. Protocol adherence was monitored by assessing
documentation in the medical record of intervention completion, and progress was communicated
to clinical pharmacists and physician champions each month via internal posters, meetings, and
email. To increase intervention uptake, physician champions introduced practice model changes
during departmental meetings, signed a letter in support of the intervention, and shared their
photographs on a poster for monitoring protocol adherence.

Study Population
Adults admitted to general medical and/or surgical wards who were discharged with oral
antimicrobial therapy were eligible for inclusion. Patients who were pregnant, discharged with
parenteral antimicrobials, or diagnosed with cystic fibrosis, endovascular infections, central nervous
system infections, osteomyelitis, or febrile neutropenia were excluded. Diagnoses of interest
included common infections with evidence-based guideline recommendations for antimicrobial
courses (eMethods in the Supplement): infections of the urinary tract, respiratory tract, skin and/or
skin-structure sites, and intra-abdominal sites with adequate source control (eFigure 1 in the
Supplement).16 Study participants were identified among those patients discharged with a
prescription for oral antimicrobials from the data repository of the electronic medical record. Cases
were sorted and selected using a random number generator (Excel, version 15.0 [Microsoft
Corporation]) and screened until 25 patients in each group every month were included. Electronic
medical records were manually reviewed to ascertain data and then entered in REDCap (Research
Electronic Data Capture). Patient race and ethnicity data were collected using the demographic
populated fields in the electronic medical record and reported to identify possible differences
between groups.

Patient Data and End Point Definitions
The primary end point was frequency of discharge with an optimized antimicrobial regimen,
determined by review of medical records, prescriptions, and discharge. Health system guidelines
were used to assess appropriateness of antimicrobial selection, dose, and duration. Definitions for
optimal antimicrobial therapy were modified in alignment with those proposed by Spivak et al17
(eMethods in the Supplement). Hospital length of stay and antimicrobial duration of therapy were
assessed as resource use outcomes. Safety end points included antimicrobial-related adverse effects
(ADEs), 30-day unplanned office and/or emergency department visits, 30-day readmissions, and
30- and 90-day mortality. Antimicrobial-related ADEs were categorized as mild to moderate or as
severe. Severe ADEs that were assessed to 90 days included Clostridiodies difficile infection and
isolation (from any clinical culture) of a new multidrug-resistant organism,18 whereas anaphylaxis
and/or angioedema, kidney failure, acute hepatic failure, torsades de pointes, seizure, and serious
hematologic toxic effects were measured to 30 days. Mild to moderate ADEs such as diarrhea; QTc
prolongation; rash; mild elevations in levels of aminotransferases, bilirubin, and/or creatinine; and
others outlined by Tamma et al19 were assessed to 30 days. When available, outside electronic health
records were ascertained for events that were presumed to not occur if not documented. Clinical
resolution was assessed only in patients with available follow-up data, defined as resolution of signs
and symptoms such that no further antimicrobial therapy was required after completion of planned
therapy for the same indication, to 30 days.20
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Statistical Analysis
Data were analyzed from February 18, 2020, to February 28, 2022. SPSS, version 26.0 (IBM Corp),
and SAS, version 9.4 (SAS Institute Inc), were used for calculations. Sample size was estimated by
presuming a 20% relative reduction of nonoptimized antimicrobial therapy at discharge from 60%
to 48% (historic data indicate 54%-63% of patients receiving antimicrobials receive excessive
durations4). Very roughly approximating the generalized estimating equation (GEE) logistic
regression sample size by that for a χ2 comparison of proportions, 357 patients in each study arm
were needed for a 2-sided α = .05 with 90% power. The Mann-Whitney test was used for
nonparametric data and an unpaired 2-tailed t test was used for parametric data. We used the χ2 and
Fisher exact tests for categorical variables, as appropriate. Two-sided P < .05 and 95% CIs were used
to describe statistical significance. To account for correlation in data from patients treated at the
same location, the primary inferential analyses used GEE logistic regression (SAS procedure
PROC_GENMOD) and analysis of covariance models, with service team location at discharge used to
define clusters. To adjust for potential temporal trend, time in months since the beginning of the
study period was used as a covariate in primary analyses. Multivariable, time-adjusted GEE logistic
regression was used to identify independent associations with an optimized antimicrobial regimen at
discharge. Candidate variables for the multivariable model included age, sex, study month, and select
covariates with predetermined clinical suspicion for optimal prescribing. The final model used
covariates with P < .10 in time-adjusted GEE analysis.

Results
Of 1440 patients screened, 800 were included across the 3 study phases: 400 in the preintervention
period and 400 in the postintervention period (Table 1 and eFigure 2 in the Supplement). The most
common reasons for exclusion were at least 1 of the following: complicated or severe infection
(n = 423), solid organ transplant or neutropenia (n = 102), transfer to or from an outside hospital or
hospice (n = 96), and discharge with intravenous antimicrobial therapy (n = 47) (eFigure 2 and
eMethods in the Supplement). A total of 441 included patients (55.1%) were women and 359 (44.9%)
were men. The mean (SD) age was 66.8 (17.3) years; mean (SD) body mass index (calculated as
weight in kilograms divided by height in meters squared), 29.9 (9.1). The median length of stay was 3
(IQR, 2-5) days. Most patients (427 [53.4%]) were admitted to the academic medical center and
discharged home (673 [84.1%]). During the study period, more than 1500 interventions were
documented, and overall protocol adherence throughout the health system was 63%. Service teams
included medicine, surgery, hospitalist, pulmonology, infectious disease, family medicine, cardiology,
and nephrology. The most common diagnoses were pneumonia (264 [33.0%]), upper respiratory
tract infection and/or acute exacerbation of chronic obstructive pulmonary disease (214 [26.8%]),
urinary tract infection (203 [25.4%]), and skin or soft tissue infection (125 [15.6%]). The median
Charlson Comorbidity Index score was 2 (IQR, 1-3); there were no significant differences in comorbid
conditions, severity of illness on presentation, or risk factors for multidrug-resistant organisms
between groups (Table 2 and eTable 1 in the Supplement).
The primary end point, optimal antimicrobial prescription at discharge, was associated with
intervention implementation (144 of 400 [36.0%] vs 326 of 400 [81.5%]; P < .001) (Table 3) and
remained consistently associated with improved prescribing across all study phases (eTable 2 in the
Supplement). The absolute increase in optimal prescribing in the postintervention group was
consistent in both academic (37.4% [95% CI, 27.5%-46.7%]) and community (43.2% [95% CI, 32.4%52.8%]) hospital models. Patients in the postintervention group were more likely to have an optimal
antimicrobial prescription (time-adjusted GEE odds ratio [OR], 5.63 [95% CI, 3.69-8.60]).
Reductions in prolonged durations of therapy (177 of 400 [44.2%] vs 37 of 400 [9.2%]; mean
difference, −35.0% [95% CI, −40.2% to −29.2%]), non–guideline-concordant antimicrobial selection
(81 of 400 [20.2%] vs 24 of 400 [6.0%]; mean difference, −14.3% [95% CI, −18.8% to −9.6%]), and
treatment of asymptomatic bacteriuria (37 of 400 [9.2%] vs 10 of 400 [2.5%]; mean difference,
JAMA Network Open. 2022;5(5):e2211331. doi:10.1001/jamanetworkopen.2022.11331 (Reprinted)
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−6.8% [95% CI, −10.0% to −3.4%]) were the largest contributing components of improved
optimized discharge prescription (Table 3). The intervention was associated with decreased total
antimicrobial duration (time-adjusted absolute difference, −1.1 [95% CI, −1.7 to −0.6] antibiotic days)
(eTable 3 in the Supplement). Duration of antimicrobial therapy for respiratory tract infection was
reduced (time-adjusted absolute difference, −1.8 [95% CI, −2.3 to −1.2] antibiotic-days) in the
postintervention period, whereas there was no difference for urinary tract infection or skin and/or
soft tissue infections. There were no differences in unadjusted analyses for clinical resolution,
readmission at 30 days, or mortality (Table 4). The intervention was associated with fewer ADEs,
mostly owing to reductions in more severe ADEs such as a new multidrug-resistant organism and C
difficile infection (Table 4) by day 90 (severe ADEs, 36 [9.0%] vs 13 [3.2%]; time-adjusted GEE OR,
0.40 [95% CI, 0.18-0.88]).
After controlling for service team, study month, and other confounders (Table 5), the TOC
intervention remained independently associated with the primary outcome, with patients in the
postintervention period having nearly 4 times greater odds of being prescribed an optimal
antimicrobial regimen at discharge (time-adjusted GEE OR, 3.77 [95% CI, 2.32-6.15]). Length of stay
(time-adjusted GEE OR, 0.89 [95% CI, 0.83-0.96]), indications for urinary tract infection (timeadjusted GEE OR, 0.59 [95% CI, 0.44-0.79]), and care at a community hospital (time-adjusted GEE

Table 2. Patient Demographic and Clinical Characteristics
Patient groupa
Characteristic

Preintervention
(n = 400)

Postintervention
(n = 400)

Timeadjusted
GEE P value

Age, mean (SD), y

69.0 (17.1)

64.5 (17.2)

.67

Women

221 (55.3)

220 (55.0)

Men

179 (44.7)

180 (45.0)

Black

113 (28.3)

200 (50.0)

White

259 (64.7)

161 (40.3)

Other or unknownb

28 (7.0)

39 (9.7)

Charlson Comorbidity Index score, median (IQR)

2 (1-3)

2 (1-3)

.96

≥2 SIRS criteria on day 3

22 (5.5)

18 (4.5)

.54

Length of stay, mean (SD), d

3.6 (2.2)

3.3 (2.2)

.70

Any MDRO risk factor

216 (54.0)

210 (52.5)

.12

Admitted in last 90 d

130 (32.5)

117 (29.3)

.99

Antimicrobial therapy in last 90 d

144 (36.0)

154 (38.5)

.65

Prior MDRO colonization

22 (5.5)

27 (6.7)

.48

Immunocompromised

7 (1.7)

15 (3.7)

.04

Nonambulatory status

32 (8.0)

19 (4.7)

.51

144 (36.0)

120 (30.0)

.24

Community-acquired without risk factors for
MDRO

108 (27.0)

92 (23.0)

.03

Community-acquired with risk factors for
MDRO

33 (8.3)

24 (6.0)

.45

Hospital-associated

Sex
.60

Race and ethnicity

Pneumonia

.04

3 (0.7)

4 (1.0)

.60

Acute exacerbation of COPD or upper respiratory
tract infection

101 (25.3)

113 (28.3)

.49

Urinary tract infection

115 (28.7)

88 (22.0)

.23

Pyelonephritis

25 (6.3)

23 (5.7)

.91

Complicated urinary tract infection

46 (11.5)

39 (9.7)

.91

Cystitis

44 (11.0)

26 (6.5)

.14

53 (13.3)

72 (18.0)

.90

20 (5.0)

39 (9.7)

.17

Skin and/or soft tissue infection
Purulent
Nonpurulent
Intra-abdominal infection

33 (8.3)

33 (8.3)

.15

4 (1.0)

12 (3.0)

.69
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OR, 0.49 [95% CI, 0.38-0.64]) were associated with a lower likelihood of receiving an optimal
regimen at discharge.

Discussion
In this quality improvement study, the implementation of a pharmacist-led discharge stewardship
intervention was associated with improved antimicrobial prescribing in this health system–wide TOC
intervention. This outcome was further associated with a reduction in antimicrobial-associated
harms, which are common after inappropriate, suboptimal, and/or unnecessary antimicrobial
prescribing at hospital discharge.17,21 Clinicians face multiple, complex decisions during TOC such as
patient placement, costs, education, follow-up, new medications, etc. Pharmacists are crucial team

Table 3. Patients Receiving Optimal Prescription at Discharge
Patient group, No./total No. (%)
Prescription component

Preintervention

Postintervention

Absolute difference,
% (95% CI)

Time-adjusted
GEE OR (95% CI)

Overall

144/400 (36.0)

326/400 (81.5)

45.5 (39.2 to51.3)

5.63 (3.69 to 8.60)

Group 1

14/25 (56.0)

185/225 (82.2)

26.2 (7.0 to 45.8)

1.09 (0.59 to 2.01)

Group 2

59/150 (39.3)

103/125 (82.4)

43.1 (32.2 to 52.7)

3.93 (1.72 to 8.99)

Group 3

71/225 (31.6)

38/50 (76.0)

44.4 (30.0 to 56.5)

5.53 (1.59 to 19.23)

Community hospitals

86/275 (31.3)

73/98 (74.5)

43.2 (32.4 to 52.8)

4.28 (2.10 to 8.69)

Academic hospital

58/125 (46.4)

253/302 (83.8)

37.4 (27.5 to 46.7)

3.27 (1.87 to 5.72)

Prolonged durationa

177/400 (44.2)

37/400 (9.2)

−35.0 (−40.2 to −29.2)

0.17 (0.11 to 0.26)

Treatment for asymptomatic bacteriuriaa

37/400 (9.2)

10/400 (2.5)

−6.8 (−10.0 to −3.4)

0.31 (0.11 to 0.86)

Nonbacterial upper respiratory tract infectiona

7/400 (1.7)

1/400 (0.3)

−1.5 (−3.0 to 0)

0.15 (0.03 to 0.86)

Non–guideline-concordant selectionb

81/400 (20.2)

24/400 (6.0)

−14.3 (−18.8 to −9.6)

0.28 (0.10 to 0.78)

Suboptimal dosec

23/400 (5.7)

4/400 (1.0)

−4.8 (−7.3 to −2.2)

0.11 (0.03 to 0.43)

Organism resistant to antimicrobial agentb

8/400 (2.0)

2/400 (0.5)

−1.5 (−3.2 to 0.2)

0.37 (0.07 to 2.09)

Duration too shortc

6/400 (1.5)

6/400 (1.5)

0 (−1.8 to 1.8)

0.63 (0.10 to 4.11)

Components of nonoptimal prescribing throughout
antimicrobial therapy course

Abbreviations: GEE, generalized estimating equation; OR, odds ratio.
a

b

Indicates unnecessary subcategory for nonoptimal therapy (eMethods in the
Supplement), including antimicrobial days beyond indicated duration of therapy,
asymptomatic bacteriuria and other noninfectious syndromes, viral respiratory tract
infection without bacterial coinfection, and redundant antimicrobial coverage.

which the pathogen is resistant to therapy and antimicrobial selection that is not
concordant with institutional guidelines.
c

Indicates inappropriate subcategory for nonoptimal therapy (eMethods in the
Supplement), including antimicrobial days for an established bacterial infection in

Indicates suboptimal subcategory for nonoptimal therapy (eMethods in the
Supplement), including use of an excessively broad-spectrum antimicrobial when a
preferred or first-line agent is not contraindicated, dose is too high or too low for
kidney function, and duration of therapy is shorter than indicated.

Table 4. Patient Outcomes
Patient group, No. (%)
Outcome

Preintervention
(n = 400)

Postintervention
(n = 400)

Absolute difference,
% (95% CI)

30-d Mortality

3 (0.7)

6 (1.5)

0.8 (−0.9 to 2.4)

0.80 (0.09 to 7.18)

90-d Mortality

12 (3.0)

11 (2.7)

−0.2 (−2.7 to 2.2)

0.78 (0.36 to 1.71)

30-d Readmission

Time-adjusted
GEE OR (95% CI)

77 (19.3)

81 (20.3)

1.0 (−4.5 to 6.5)

0.77 (0.60 to 0.98)

33 (8.3)

21 (5.3)

−3.0 (−6.5 to 0.5)

0.48 (0.28 to 0.81)

30-d Unplanned office or
emergency department
visit

105 (26.3)

109 (27.3)

1.0 (−5.1 to 7.1)

0.59 (0.37 to 0.94)

Infection related

No clinical resolutiona

50 (16.5)

34 (12.4)

−4.1 (−9.8 to 1.6)

0.91 (0.63 to 1.30)

Any adverse drug event

78 (19.5)

53 (13.3)

−6.3 (−11.4 to −1.0)

1.09 (0.57 to 2.06)

Severe adverse drug event

36 (9.0)

13 (3.2)

−5.7 (−9.1 to −2.4)

0.40 (0.18 to 0.88)

Clostridioides difficile
infection

7 (1.7)

2 (0.5)

−1.2 (−2.8 to 0.4)

0.64 (0.11 to 3.64)

MDRO at 90 d

28 (7.0)

10 (2.5)

−4.5 (−7.6 to −1.6)

0.32 (0.15 to 0.71)

Abbreviations: GEE, generalized estimating equation;
MDRO, multidrug-resistant organism; OR, odds ratio.
a
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members in leading the supportive antimicrobial reviews (eg, determining antimicrobial days),
multidisciplinary discussions, addressing medication access barriers, and facilitating antimicrobial
orders into discharge queues for cosigning by the prescriber.
The Centers for Disease Control and Prevention has highlighted the importance of antimicrobial
stewardship in the TOC setting in the 2019 core elements of hospital antibiotic stewardship as an
opportunity to improve prescribing at hospital discharge.22,23 In a multicenter cohort study assessing
antimicrobial orders for respiratory and urinary infections from 21 825 discharged patients, Vaughn
et al3 classified 49% of prescriptions as overuse. These findings were largely owing to excessive
durations of therapy and were similar to those in our preintervention group prescribing frequency of
prolonged antimicrobial duration at discharge (44.3%). Similar results were observed in a
multicenter, cross-sectional study24 assessing antimicrobial appropriateness in hospitalized adults.
Using objective antimicrobial quality assessment algorithms, more than 75% of antimicrobial courses
for community-acquired pneumonia and urinary tract infection were considered unsupported
generally because of long duration and incorrect selection of antimicrobial therapy and use for
treatment of asymptomatic bacteriuria.24
Rigorous education and implementation planning largely contribute to the success of an
intervention. Investment from all key partners from medicine, pharmacy, and nursing groups
promotes ownership, responsibility, and accountability. Six months of upfront effort was invested
from the investigator team to develop the design, feedback structure, training, and education
required to implement the intervention across 5 hospitals. Using routine monitoring of protocol
adherence, we were able to provide transparency of challenges and successes related to intervention
progress via meetings, monthly electronic updates, benchmarking, and positive feedback cases. The
additional dedicated time to new interventions in the pharmacist workload varied for each site
depending on the population, communication model, and total volume of patients cared for on each
shift. A mean of 1 to 3 patients were discharged with a prescription for oral antimicrobials each day
from any given service team. In addition to audit and feedback, the pharmacy and antimicrobial
stewardship personnel’s active role in executing the intervention via electronic medication entry into
the discharge queue was crucial in antimicrobial optimization (eTable 4 in the Supplement).
Sustained growth and success of the model was maintained in both academic and community service

Table 5. Assessment of Covariates and Optimized Discharge Prescription in Univariate and Multivariable Models
Optimized discharge prescriptiona
Covariate

Yes

P value

Time-adjusted
GEE OR (95% CI)c

GEE P valuec

Overall

470/800 (58.7)

330/800 (41.3)

NA

NA

NA

NA

Postintervention period

326/400 (81.5)

74/400 (18.5)

6.63 (4.45 to 9.86)

<.001

3.77 (2.32 to 6.15)

<.001

Age, mean (SD), y

64.7 (17.6)

69.7 (16.5)

0.83 (0.76 to 0.90)

<.001

0.93 (0.82 to 1.04)

.18

Women

262/441 (59.4)

179/441 (40.6)

0.94 (0.70 to 1.27)

.71

Not tested

NA

Length of stay, median (IQR), d

3 (2-4)

4 (2-5)

0.86 (0.80 to 0.92)

<.001

0.89 (0.83 to 0.96)

.001

Study month

NA

NA

1.25 (1.19 to 1.31)

<.001

1.11 (1.04 to 1.19)

.003

Charlson Comorbidity Index score, median (IQR)

2 (1-3)

2 (1-4)

0.95 (0.88 to 1.03)

.22

Not tested

NA

≥1 MDRO risk factor

251/426 (58.9)

175/426 (41.1)

1.11 (0.83 to 1.50)

.48

Not tested

NA

Community hospital

159/373 (42.6)

214/373 (57.4)

0.23 (0.17 to 0.32)

<.001

0.49 (0.38 to 0.64)

<.001

Urinary source

96/203 (47.3)

107/203 (52.7)

0.58 (0.41 to 0.81)

.002

0.59 (0.44 to 0.79)

<.001

≥2 SIRS criteria on day 3

21/40 (52.5)

19/40 (47.5)

0.79 (0.40 to 1.54)

.49

Not tested

NA

Empirical intravenous antimicrobial

370/650 (56.9)

280/650 (43.1)

0.69 (0.47 to 1.02)

.06

0.76 (0.54 to 1.06)

.11

Dementia

33/71 (46.5)

38/71 (53.5)

0.66 (0.40 to 1.11)

.12

Not tested

NA

Absence of microbiologic or diagnostic data

95/143 (66.4)

48/143 (33.6)

1.19 (0.80 to 1.78)

.39

Not tested

NA

Abbreviations: GEE, generalized estimating equation; MDRO, multidrug-resistant
organism; NA, not applicable; OR, odds ratio; SIRS, systemic inflammatory response
syndrome.
a

OR (95% CI)b

No

Unless otherwise indicated, data are expressed as number/total number (%) of
patients.

b

Calculated using standard logistic regression. Covariates with an OR greater than 1.00
are associated with an optimized discharge prescription.

c

Calculated using multivariable logistic regression. Covariates with an OR greater than
1.00 are associated with an optimized discharge prescription.
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teams across each quarter during active intervention (eFigure 3 in the Supplement). Replication of
similar TOC models may require a foundation of pharmacy leadership, engagement, and clinical
expertise, which are resources that are not available to all health care facilities. Zampino et al8
observed similar improvement in overall appropriateness of antimicrobial therapy during TOC at an
academic hospital after audit and feedback by an antimicrobial stewardship pharmacist for discharge
prescriptions from medicine/surgical wards. An interesting finding from our study was that patients
discharged from community centers had lower odds of being prescribed an optimal antimicrobial
regimen at discharge. These lower odds could be owing to availability of staff in community settings
or associated with the study design by having fewer patients in the intervention arm in community
hospitals (Table 1).
The synergistic relationships between prescriber and pharmacist in antimicrobial stewardship
programs facilitate better care and services.25 Medication reconciliation, preauthorization of
therapies, and facilitating appropriate diagnostic testing are a few of many examples in which these
collaborations have proven beneficial.11 Specifically, during TOC, Chavada et al26 found large
discrepancies between guideline recommendations and the actual antimicrobial discharge
prescription. With regard to antimicrobial choice, dose, frequency, and duration, patients who had
received an intervention by the antimicrobial stewardship team were more likely to have appropriate
therapy.26 Yogo et al9 used audit and feedback on discharge prescriptions to transition patients with
respiratory, skin, urinary, and gastrointestinal tract infections to an optimized antimicrobial selection
and duration. Staff pharmacists were trained to conduct this review in real time for patients being
discharged from the hospital; duration of therapy after hospital discharge was reduced by a day and
prescribing preferences shifted away from fluoroquinolones.9 However, appropriateness of the
discharge prescription and other clinical end points were unchanged, and among 918 patients
prescribed an oral antimicrobial at discharge during the study period, a prescriber was contacted only
about 10% of the time.9 Our ability to capture more patients in the protocol was likely an important
component for improving patient safety.
The intervention was not directly associated with clinical resolution, although we observed an
association with reduced severe antimicrobial-related ADEs. Interestingly, no difference in
readmissions was observed in the unadjusted analysis; however, after controlling for service team
and study month, patients in the postintervention period had a lower risk of 30-day readmission and
infection-related readmission. Readmission is a highly confounded outcome, and results should be
interpreted with caution. In a large prospective national study, several thousand patients were
assigned to receive a variety of interventions related to TOC, which reduced readmissions.27 This
finding was driven by hospital-based TOC interventions that included but were not limited to
medication reconciliation, identification of high-risk patients, and promotion of trust in the hospital.
The hospital-based actions were not specific to patients prescribed antimicrobials, although this
population should be a high-risk group given the number of comorbid conditions and readmissions
associated with infections. In our study, most antimicrobial optimization from the intervention was
related to selecting shorter durations and more targeted therapy, which coincides with the ADE
frequency before and after the intervention. Each excess antimicrobial day has been associated with
5% greater odds of developing an ADE.21 We also found that fewer than 1% (n = 5) of patients had
readmissions potentially related to ADEs. Similarly, Vaughn et al3 concluded that antimicrobial
overuse after discharge was not associated with readmissions, mortality, or patient-reported ADEs;
however, incidence of new multidrug-resistant organisms was not assessed.

Limitations
There are inherent limitations in the nonrandomized design of this study, including biases due to
maturation and Hawthorne effect and regression to the mean. Using a nonrandomized steppedwedge design with multiple observation periods and points of intervention, we were able to better
mitigate biases. Notably, the frequency of protocol adherence (63%, defined by the presence of
medical record documentation of antimicrobial plan and guideline recommendation by discharge)
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was surpassed by the frequency of optimal discharge-antimicrobial prescribing (81.5%) in the
postintervention group. This occurrence is likely attributable to maturation and the Hawthorne effect
given that clinicians became aware of the intervention. We also found differences in diagnoses and
race between the preintervention and postintervention groups, likely due to the stepped-wedge
intervention rollout order, subsequently leading to imbalances in the numbers of patients from
community hospitals. In addition, the process of collaborative rounds for service teams in academic
centers was modified to include antimicrobial TOC discussions. Communication models differed
between hospitals for paging, telephone calls, and rounding on service teams. There were no other
major concurrent health system–wide interventions related to antimicrobial stewardship and/or TOC
during the study periods.

Conclusions
The findings of this quality improvement study suggest that leveraging resources to provide
additional review and intervention on antimicrobial discharge therapies may lead to improvements
in the quality and safety of antimicrobial prescriptions. Using pharmacists to reinforce institutional
protocols, we were able to successfully target and modify the following areas of antimicrobial
optimization: minimization of unnecessary antimicrobial days from prolonged durations and patients
without infections; avoidance of therapies that are excessively broad, not concordant with local
guidance, or targeted toward pathogens that are not susceptible to the antimicrobial; and
transitioning from intravenous agents to accessible and affordable oral options as soon as possible.
Health care systems seeking to improve quality of prescribing and safety for patients with common
infections should consider adopting antimicrobial stewardship interventions at TOC.
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